Votre navigateur ne supporte pas le javascript Wallonia & Brussels against COVID-19 - Company

Company

Alexandre Di Paolo, Business Development Manager

Xpress Biologics
" Xpress Biologics, a Belgian based CDMO, has several strategies to tackle the COVID-19 pandemic which includes: - The development of a serology assay to detect Covid-19 seroconversion in humans based on the manufacturing of 3 specific COVID-19 antigens ( full-length Spike protein, S1 subunit, RBD domain) using Pichia pastoris as expression system - Plasmid DNA manufacturing expertise for the development of anti-COVID DNA vaccines - Recombinant protein or antibody fragments manufacturing expertise for diagnostic and treatment of COVID-19 Xpress Biologics has adapted technological platforms that are available to meet the COVID-19 pandemic challenge. In particular our Molecular Biology solution can rapidly help us develop microbial strains for robust and efficient expression of several type of biologics such as viral antigens, neutralizing antibody fragments and DNA vaccines while through our Upstream Process platform we can rapidly engineer industrial processes for...

Alexandre Legrand, Professor

UMONS/ Haute école Condorcet/ UCLouvain/ Epicura/ Machine sight
" In view of the risk of a respirator shortage in intensive care units throughout the world following the COVID 19 epidemic, a simple solution based on existing means or means that are easy to implement is being sought by a consortium of respiratory physiotherapists, researchers of UMONS, physicians of the the intensive care unit of the Epicura hospital and a mechatronics engineering company. In view of the risk of a respirator shortage in intensive care units throughout the world following the COVID 19 epidemic, a simple solution based on existing means or means that are easy to implement is being sought by a consortium of respiratory physiotherapists, researchers of UMONS, physicians of the the intensive care unit of the Epicura hospital and a mechatronics engineering company. "
Funding: internal funding
Contact: Pr. Alexandre Legrand, head of the laboratory of Physiology and Respiratory Rehabilitation...

Alfred Attipoe, CEO

Comunicare Solutions
" Comunicare Solutions is a health technology startup, specializing in patient empowerment, self-management and digital therapy. In the context of Covid-19 sanitary crisis, we proposed our solution for the remote support to chronic patients, especially the most at risk patients who suffered from chronic systemic diseases of respiratory origin, such as chronic obstructive pulmonary disease (COPD) and heart disease like heart failure or complex hypertension. The application enables caregivers to inform those patients about additional precautions, to screen patients reported outcomes but also to keep in touch with them via video consultation"
Contact: contact@comunicare.be

Cedric Szpirer, Executive & Scientific Director

Delphi Genetics SA
" The aim of the project is to develop an antiviral gene therapy specifically targeting Covid-19. The benefits should be (i) targeting precisely the virus directly in lung cells allowing limitation of virus development from the starting point, (ii) restoring essential functions of the patient's cells and (iii) antibodies production by the patient due to reduction of viral load but not immediate clearance. In addition, the therapy could also be used preventively for people who come into regular contact with affected patients. The therapy is a gene therapy using AAV for patient administration. Delphi Genetics is developing and producing the plasmids required for targeting the virus and production of AAV. "
Contact: Cedric Szpirer Delphi Genetics SA 071 25 10 00

Damien BERTRAND, Business Development Officer

DNAlytics
" Research projects : contributions to research projects with academics and hospital representatives (-omics data investigations, biomarkers and multi-marker indicators, stratification of populations, predictive models for diagnosis/prognosis, ... Development / production capabilities: internal processes and quality system compatible with ISO.13485 (medical devices). Skills and expertise: data sciences, machine learning and other technologies from artificial intelligence; statistics, bio-IT; model encapsulation into software, mobile apps or web platforms "
Funding: Prestations sub-contracted by lead researchers, or partnerships through regional/EU projects with public funding.
Publication References: Complete list on www.dnalytics.com/publications/ 
Contact : info@dnalytics.com

Denis GOSSEN, CSO, co-founder

AEPODIA
" Experts in the early development of drugs and medical devices up to clinical proof-of-concept (from preclinical to Phase 2). Via its network of partners, Aepodia facilitates access to patients and to validated clinical centres throughout Europe. With offices in Belgium and France, Aepodia is a recognized partner for pharmaceutical and biotechnology companies since 2007. "
Contact: www.aepodia.com info@aepodia.com

Didier Serteyn, Professor - Justine Ceusters, CSO RevaTis - Charlotte Sandersen, Professor

ULiège and RevaTis SA (Spin Off)
" The project aims to assess the effects of muscle derived stem cells on a preclinical model of acute respiratory distress syndrome induced by a perfusion of endotoxins. We focused on the modulation of neutrophil excessive activation. RevaTis developped a GMP production of muscle derived Mesenchymal Stem Cells and is authorized to produce clinical batches. The IPCLab (Liege University) developed an ARDS model in pigs. We aim to demonstrate a reduction of the ARDS severity, a reduction of the cytokines storm and a modulation of the excessive activation of neutrophils observed in ARDS. "
Funding: Research grants from Ulg (POC) and FNRS (CURE) are pending. RevaTis supplies muscle derived Stem Cells for R&D projects
Publication References: Sci Rep. 2017 Apr 6;7(1):696. doi: 10.1038/s41598-017-00803-7. From skeletal muscle to stem cells: an innovative and minimally-invasive process for multiple species. Ceusters J, Lejeune JP, Sandersen C, Niesten A...

Jean-Marie Saint-Remy, Professor

Equaly sa
" A novel strategy to prevent virus entry through the ACE2R A novel strategy for preventive vaccination to Covid-19 Monoclonal antibodies targeting the ACE2R are used to block virus entry. Vaccines are prepared eliciting a Th1response together with cytotoxic T cells. "
Funding: private
Contact: info@equaly.be

Jean-Paul Deslypere, MD

Aesculape CRO Belgium BV
" Treatment of COVID 19 complications with antibodies "
Funding: partly public partly private
Contact : jpdeslypere@aesculape.com 0492 735931

Jurga Marcin, PhD

EXO Biologics
" EXO Biologics plans to extend its research and development program towards the COVID-19 crisis by using its unique and disruptive technology based on Extracellular Vesicles. These nanometer size particles are gaining momentum in the scientific community as potential alternatives to stem cell and biologic drugs therapies in the fields of immunology, neurology, oncology, cardiology, gastroenterology among others. EXO Biologics has 12 years of experience in cell-based regenerative medicine and 8 years of experience in Extracellular Vesicles. Our advancements in research will play an important role for our company mission to provide affordable and accessible therapies to patients with unmet medical needs. "
Contact: info@exobio.be

Khanh TRAN DUY

3D-Side S.A.
" "- 3D printing of swabs in SLS - 3D printing of valves - 3D printing of connectors for respiratory systems - Advice on guidelines on the manufacturing and post processing of such devices." "
Contact: Khanh TRAN DUY ktd@3dside.eu

Kyun Thibaut, Founder and Managing Director

Covartim
"In the global effort to help the healthcare professionals in the fight against the Covid pandemic, we are providing documents to help manufacturers that are not familiar with medical devices to properly document their work to help them in their product development and achieving compliance. These templates are derived from our technical file documentation and include some reference to guidances (mostly applicable in Belgium) for devices and accessories to answer to hospital products shortage."
Contact : Covartim www.covartim.be kthibaut@covartim.com

Patrick Baleriaux, CEO

Aseptic Technologies SA
" Table-top equipment for FFP2 mask decontamination by means of UV-C, developed jointly by Lasea s.a. and Aseptic Technologies s.a. Allows re-use of FFP2 masks up to 5 times (under validation process) "
Contact: Patrick Baleriaux CEO Aseptic Technologies s.a PBA@aseptictech.com

Patrick Powis, Engineer

Malcourant Mécanique
" We have developed a semi-automatic machine to weld polyethylene sheets in order to make the COVID-19 protective mask envelope. This development has been carried out entirely in-house, study - manufacture - assembly. We called the company ICS to improve the working conditions for the welding jaws. "
Contact: malcourant-mecanique.be incosol4u.com

Contact us

c/o F.R.S. - FNRS

Rue d’Egmont 5

B - 1000 Bruxelles

Tél : +32 2 504 92 11

info@COVID19-WB.be

Brussels & Wallonia against COVID19

AcceptRead more about cookies

Disclaimer - Terms and conditions of use


The purpose of the provisions below is to define the conditions under which the F.R.S.-FNRS gives you access to this website www.COVID19-WB.be.

1. Acceptance of the general conditions of use

The F.R.S.-FNRS gives you access to the www.COVID19-WB.be website and the information contained therein, you accept these conditions. The F.R.S.-FNRS may modify them at any time.

2. Use of the website

The content of this website is provided to you for general information purposes only. The content of this website may only be used in connection with the services offered on the website and for your personal use. This website may not be used as a basis for any evaluation of the F.R.S.-FNRS and may in no way bind or be opposable to the F.R.S.-FNRS. Nothing on the website can be considered as an offer to purchase or provide services or to conclude a contract.

The user undertakes to use the website in compliance with the laws and legal and/or contractual notices. The user may not use it in any way that would prejudice the interests of the F.R.S.-FNRS and/or its partners.

3. Guarantees and limitations of liability for the use of the website

In general, the F.R.S.-FNRS cannot, under any circumstances, be held liable for direct or indirect damage, or for any other damage of any nature whatsoever, resulting from the use of this website or from the impossibility of using it for any reason whatsoever, whether or not this liability is contractual, tortious or quasi-delictual, or whether it is based on no-fault liability or otherwise, and this even if the F.R.S.-FNRS is not liable for any damage resulting from the use of this website or from the impossibility of using it for any reason whatsoever, whether or not this liability is contractual, tortious or quasi-delictual, or whether it is based on no-fault liability or otherwise, and this even if the F.R.S.-FNRS is not liable for any damage resulting from the use of this website. FNRS would have been advised of the possibility of such damages.

3.1 Information

The information on this site is the exclusive responsibility of its authors. The F.R.S.-FNRS uses all reasonable means to publish on this website information which, to its knowledge, is up to date. However, it does not guarantee the adequacy, accuracy or exhaustiveness of such information nor does it guarantee that the website will always be complete and up to date in all respects. The information contained on this website may contain inaccuracies in content, technical inaccuracies or typing errors. This information is provided for information purposes only and is subject to periodic changes. The F.R.S.-FNRS may be required to make improvements and/or changes to this website at any time and without notice.

The use of this website, and consequently the information obtained, or elements downloaded when using the service, is the sole responsibility of the user. The F.R.S.-FNRS declines all responsibility for any damage that may result from the use of the information on this website.

The user also acknowledges that he or she shall be solely responsible for any damage to his or her computer system or any loss of data resulting from the downloading of any content.

3.2. Hypertext links

This website contains hypertext links to other sites as well as references to other sources of information, which are provided for your information only. The F.R.S.-FNRS does not control these sites and the information contained therein and therefore cannot offer any guarantee as to the quality and/or exhaustive nature of this information.

The F.R.S.-FNRS declines all responsibility for any unsuitable, illegitimate or illegal content present on the hyperlinks as well as for any damage that may result from consulting them.

3.3. Acts of Internet users

The F.R.S.-FNRS shall in no way be held responsible for the actions of Internet users.

4. Intellectual property rights

The trademarks on the site (www.COVID19-WB.be) may not be used in connection with any product or service other than those of the F.R.S.-FNRS, in any way that is likely to create confusion or in any way that would depreciate or discredit the F.R.S.-FNRS.

Unless explicitly authorized to do so, the user may not, under any circumstances, copy, reproduce, translate, represent, modify, transmit, publish, adapt, distribute, broadcast, license, transfer, sell, on any medium whatsoever, by any means whatsoever, or exploit in any way whatsoever, all or part of this website without the prior written authorization of the F.R.S.-FNRS. Any infringement may result in civil and criminal prosecution.

AcceptRead more about cookies